



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 698 215 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
15.07.1998 Bulletin 1998/29

(51) Int Cl.⁶: **G01N 33/574, G01N 33/567,
G01N 33/58, C12Q 1/68**

(21) Application number: **94915490.0**

(86) International application number:
PCT/CA94/00267

(22) Date of filing: **13.05.1994**

(87) International publication number:
WO 94/27152 (24.11.1994 Gazette 1994/26)

(54) **DETECTION OF PROSTATE-SPECIFIC ANTIGEN IN BREAST TUMORS**

NACHWEIS VON PROSTAT-SPEZIFISCHEN ANTIGEN IN BRUSTTUMOREN

DETECTION D'ANTIGENES PROSTATIQUES SPECIFIQUES DANS DES TUMEURS DU SEIN

(84) Designated Contracting States:
AT BE DE DK ES FR GB IT NL PT SE

(56) References cited:
WO-A-92/01936 GB-A- 2 187 283

(30) Priority: **14.05.1993 GB 9309966**

(43) Date of publication of application:
28.02.1996 Bulletin 1996/09

(73) Proprietor: **NORDION INTERNATIONAL, INC.**
Kanata, Ontario, Canada K2K 1X8 (CA)

(72) Inventor: **DIAMANDIS, Eleftherios, P.**
Toronto, Ontario M5G 2K2 (CA)

(74) Representative: **Lerwill, John et al**
A.A. Thornton & Co.
Northumberland House
303-306 High Holborn
London, WC1V 7LE (GB)

- ACTA CYTOLOGICA, vol.33, no.6, 1989 pages 899 - 902 F.C.SCHMITT ET AL. 'Cytology and Immunocytochemistry of Bilateral Breast Metastases from Prostatic Cancer'
- BAS. APPL. HISTOCHEM., vol.33, 1989 pages 25 - 29 M.PAPOTTI ET AL. 'Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumors.' cited in the application
- CLINICAL CHEMISTRY, vol.21, no.3, June 1988 pages 139 - 150 E.P.DIAMANDIS 'Immunoassays with Time-Resolved Fluorescence Spectroscopy: Principles and Applications' cited in the application
- EUR. J. CLIN. CHEM. CLIN. BIOCHEM., vol.29, 1991 pages 787 - 794 W.G.WOOD ET AL. 'The Establishment and Evaluation of Luminescent-Labelled Immunometric Assays for Prostate-Specific Antigen-alpha1-Antichymotrypsin Complexes in Serum'
- CLINICAL CHEMISTRY, vol.39, no.10, 1993 pages 2108 - 2114 H.YU ET AL. 'Ultrasensitive Time-Resolved Immunofluorometric Assay of Prostate-Specific Antigen in Serum and Preliminary Clinical Studies'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 698 215 B1

Description

This invention relates to the detection of prostate-specific antigen (PSA) in female breast tumour extract as a prognostic or predictive indicator for breast carcinoma. The presence of prostate-specific antigen in breast tumours is associated with earlier disease stage, younger women and better survival. PSA is associated with tumours which have oestrogen and/or progesterone receptors.

Considerable research and related diagnosis has been undertaken in this field of healthcare. In order to facilitate reference to prior art developments and procedures, journal articles are listed at the end of this specification and are hereinafter referenced by number.

Breast cancer is a leading cause of mortality and morbidity among women (1-4). One of the priorities in breast cancer research is the discovery of new biochemical markers which could be used for diagnosis, prognosis and monitoring (4, 5). Breast cancer is one of a few cancers that is dependent on steroid hormones and their receptors. Currently, oestrogen and progesterone receptor analysis is performed routinely as an aid in prognosis and selection of therapy (4-6).

Current indicators for diagnosing and monitoring breast tumours include: tumour size, oestrogen receptors, progesterone receptors, age, aneuploidy, mitotic activity and Ki67 (29). The prognostic usefulness of these factors depends on their ability to evaluate which patients with breast cancer require aggressive therapeutic treatment and which patients should be monitored.

Mutation of the p53 tumour suppressor gene is one of the most commonly known genetic defects in human cancer, including breast cancer and results in mutant protein accumulating to high concentrations. Overexpression of p53 protein expression has been found to be an independent predictor of early disease recurrence (29). The accumulation of p53 protein has been found to be an independent marker of shortened survival (30). The majority of tumours that do not produce mutant p53 protein are oestrogen and/or progesterone receptor-positive (14).

Prostate cancer is a leading cause of mortality and morbidity among men (7, 8). Prostate tissue and cancer is also dependent on steroid hormones and therapy that takes advantage of this is currently routinely used. (9-10). One of the hallmarks of prostate cancer is the appearance in serum, at elevated concentrations, of a 30-33-KD glycoprotein, prostate specific antigen (PSA) (11). PSA is secreted by the epithelial cells of prostatic tissue and is currently widely used as a tumour marker for diagnosing and monitoring prostatic carcinoma.

Previous immunohistochemical studies found no PSA immunoreactivity in breast or other tumours (17) or found occasional PSA immunoreactivity with polyclonal but not monoclonal antibodies, suggesting cross-reactivity effects (18). PSA levels in female serum are undetectable in 90% of women. A few women do have traces of PSA which are thought to be produced in the periurethral glands.

We have surprisingly discovered the presence of PSA in breast tumour.

We have discovered that breast tumours have the ability to produce PSA which can be used as a prognostic indicator. PSA production in breast tumours is associated with oestrogen and/or progesterone receptor presence, but not the p53 tumour suppressor gene protein. PSA - positive tumours are associated with younger women and earlier disease state. PSA is a favourable prognostic indicator because it is associated with oestrogen and progesterone receptors, with lower disease stage and with improved patient survival. PSA positive tumours respond to endocrine treatment, particularly oestrogen receptor-negative tumours.

An object of the invention is in the analysis of PSA in female breast tumour extracts which is useful for prognosis, diagnosis or monitoring.

A significant benefit which follows from this invention is that PSA analysis defines a subgroup of patients which may have a different prognosis from that of other breast tumour patients.

According to an aspect of the invention there is provided, a method for detecting the presence of PSA as a prognostic or predictive indicator of breast carcinoma in female breast tumour tissue, said method comprising conducting a biological assay for the presence of PSA on a sample of breast tumour tissue, said assay being capable of detecting a concentration of at least as low as 0.03 ng of PSA per mg of total protein in the sample.

According to an aspect of the invention, the PSA positive classification indicates hormonal treatment for the breast tumour condition is required.

According to an aspect of the invention, a method is provided for measuring PSA, based on time-resolved fluorometry (TR-FIA) (12, 13) which is approximately 40-fold more sensitive than the commercially available and widely used immunometric techniques. This method has been thoroughly evaluated and can easily and precisely quantify PSA at levels of 0.05 µg/L or higher.

In accordance with a preferred aspect of the invention, an ultrasensitive detection method for prostate-specific antigen in breast tumour extract involving time-resolved fluoroimmunoassay is provided. Breast tumour extract is incubated with monoclonal anti-PSA antibody. Biotinylated polyclonal antibody specific to PSA is added to bind to any bound PSA. Alkaline phosphatase-labelled streptavidin (SA-ALP) is added. The activity of ALP is measured by adding the substrate 5- fluorosalicyl-phosphate and then adding Tb³⁺-EDTA to form a fluorescent chelate. Fluorescence is

measured during a specific time interval to indicate the presence of PSA. The presence or absence of PSA can be used as a prognostic and predictive indicator of breast carcinoma.

Preferred embodiments of the invention are demonstrated with respect to the drawings wherein:

Figure 1. Analysis of PSA in breast tumour extracts by a TR-FIA method and three immunometric techniques which are currently commercially available. Upper panel: Comparison of TR-FIA with the Hybritech Tandem® PSA kit for 24 breast tumour extracts with PSA >0.3 µg/L. Middle panel: Comparison of TR-FIA with the DPC IRMA-Count® PSA kit for the same extracts. Lower panel: Comparison of TR-FIA with the Abbott IMx® assay. The equation represents linear regression analysis and R is the correlation coefficient. One tumour extract sample, not included in the graph, had a PSA value of 61.4 µg/L by TR-FIA, 39.4 µg/L by Hybritech and 51.8 µg/L by the DPC kit (not measured by IMx). These data confirm the presence of PSA in breast tumour extracts by four different immunological techniques.

Figure 2. Analysis of PSA by TR-FIA in high performance liquid chromatographic (HPLC) fractions. The column was calibrated with a molecular weight standard solution containing thyroglobulin (670 KD), IgG (158 KD), ovalbumin (44 KD), myoglobin (17 KD) and cyanocobalamin (1.4 KD). Upper panel: Breast tumour extract with PSA of 6.7 µg/L by TR-FIA and a male serum sample with 4.27 µg/L of PSA, by TR-FIA. Lower panel: Breast tumour extract with PSA of 61.4 µg/L by TR-FIA. The peak at fraction 45 corresponds to a molecular weight of approximately 30 KD and represents free PSA. The peak at fraction 40 corresponds to a molecular weight of approximately 100 KD and represents PSA bound to α_1 -antichymotrypsin.

Figure 3. Percentage of PSA-positive (1), oestrogen receptor-positive (2) and progesterone receptor-positive (3) tumours in four groups of patients with age (years) of <35, 35-44, 45-54 and greater or equal to 55. PSA-positive tumours were preferentially distributed among younger patients ($P=0.012$) and oestrogen receptor-positive tumours among older patients ($P=0.001$). The progesterone receptor-positive tumours were not preferentially distributed in any age group ($P=0.45$).

Figure 4. Percentage of PSA-positive tumours in each disease stage or in stages 0-1 or 2-3. Stages 0-1 indicate a localized tumour and stages 2-3 indicate increased spreading of the tumour. There is a clear trend for PSA-positive tumours to be associated with lower disease stage (see also Table 4).

Figure 5. Proposed scheme for PSA production by breast tumours. Circulating ligands associate with either oestrogen, progesterone, androgen or glucocorticoid receptors. The complexes formed act to de-repress the PSA gene. Receptor-negative tumours cannot induce PSA production. The subgroup of tumours which are receptor-positive but do not produce PSA are either deficient in ligands, possess defective receptors or they have a defect downstream from the L-R complex.

Figure 6. Kaplan Meier Survival curves for PSA-positive and PSA-negative patients. Upper panel: overall survival; lower panel: disease-free survival.

We have carried out extensive investigations on breast tumours and surprisingly, found that twenty-nine percent of the breast tumour extracts were found positive for PSA (cutoff level 0.05 µg/L or 0.03 ng/mg total protein). PSA was associated with tumours that were oestrogen and/or progesterone receptor-positive ($P<0.002$). No association was found between PSA levels and levels of the p53 tumour suppressor gene product ($P=0.37$). High performance liquid chromatography revealed that PSA is present in the tumour in its free, 30 KD form. PSA-positive tumours were associated with younger (premenopausal) women ($P=0.012$) and earlier disease stage ($P=0.064$). It appears that PSA production is induced by steroid hormone receptor-ligand complexes.

In accordance with this invention, minute amounts at the molecular level can be relied on to categorize breast tumour patients for a therapeutic regime directed at this type of breast cancer.

The cutoff value of 0.05 µg/L (0.03 ng/mg total protein) for PSA was arbitrarily selected based on the PSA assay sensitivity. PSA values >0.05 µg/L can be easily and precisely quantified by using the developed assay of the invention. It is appreciated that various assay techniques may be used to detect PSA; for example, enzyme immunoassay, radioimmunoassay, chemi- or bio-luminescent immunoassay, fluorescent immunoassay and DNA-based assays to detect expression of the PSA gene at the mRNA level.

In accordance with a preferred aspect of the invention, an assay comprising an ultrasensitive detection method for prostate-specific antigen in breast tumour extract involving time-resolved fluoroimmunoassay is provided. Breast tumour extract is incubated with monoclonal anti-PSA antibody. Biotinylated polyclonal antibody specific to PSA is added to bind to any bound PSA. Alkaline phosphatase-labelled streptavidin (SA-ALP) is added. The activity of ALP is measured by adding the substrate 5-fluorosalicyl-phosphate and then adding Tb³⁺-EDTA to form a fluorescent chelate. Fluorescence is measured over time to indicate the presence of PSA. The presence or absence of PSA can be used as a prognostic and predictive indicator of breast carcinoma. The invention's detection method can also be used for detecting the presence of other markers or substances, such as p53 protein, using the appropriate antibody.

The data we have established and as summarized in Table I, establishes a correlation between breast tumours and tissue level of PSA. 525 breast tumour extracts were analyzed for PSA with the results as shown in Table I. From these tumour extracts, 374 (71.2%) had PSA levels <0.05 µg/L and were considered negative for PSA. One hundred and fifty-one (28.8%) of the tumour extracts had PSA levels >0.05 µg/L, 96 (18.3%) had PSA levels >0.1 µg/L and 49

(9.3%) had PSA levels $>0.3 \mu\text{g/L}$. Samples with a PSA concentration of $>0.3 \mu\text{g/L}$, which is potentially measurable by commercial kits, were also analyzed by the Hybritech Tandem® M-R PSA kit, by the IRMA-Count® PSA kit and by the Abbott IMx Kit. The results are shown in Figure 1.

To further exclude the possibility of non-specific effects, the assay was repeated for 25 highly positive samples (PSA $>0.3 \mu\text{g/L}$) under the following conditions: (a) the assay was run in the absence of capture mouse monoclonal anti-PSA antibody (b) the assay was run by using an irrelevant capture mouse monoclonal antibody (against alpha-fetoprotein) (c) the assay was run after substitution of the polyclonal rabbit detection antibody with biotinylated rabbit IgG. In all cases, background signals were obtained verifying that non-specific effects were absent.

PSA immunoreactivity was further investigated in two breast tumour extracts by using high performance liquid chromatography (HPLC). One male serum sample with a PSA concentration of $4.27 \mu\text{g/L}$ by TR-FIA and one negative breast tumour extract were used as positive and negative controls. Analysis of PSA was performed in the HPLC fractions and the results are shown in Figure 2. The PSA-negative breast tumour extract, run between the positive samples, gave undetectable readings in all fractions, in all cases. The PSA immunoreactivity in the two breast tumour extracts, elutes as a single peak at fraction 45 and corresponds to a molecular weight of approximately 30 KD. The PSA immunoreactivity in the male serum sample elutes in two peaks at fractions 40 and 45 and corresponds to molecular weights of approximately 100 KD and 30 KD, respectively. These two peaks correspond to PSA bound to α_1 -antichymotrypsin and to free PSA, respectively (13,15,16). These findings demonstrate that the PSA in the breast tumour extracts is present exclusively in the free 30 KD form.

In order to exclude the possibility of contamination of the extracts, six PSA-positive and six PSA-negative breast tumours that were stored frozen at -70°C were reextracted. Rerun of the fresh extracts with the TR-FIA assay confirmed the original results in all cases. Ninety-four breast tumour extracts were also obtained from another steroid hormone receptor laboratory serving different hospitals in Toronto. From these, 17 (18%), 12 (13%) and 5 (5.3%) had PSA values >0.05 , >0.1 and $>0.3 \mu\text{g/L}$, respectively.

Recovery experiments done by spiking PSA-negative tumour extracts with seminal plasma PSA gave values averaging 83% of the amount of exogenous PSA added. Dilution experiments were performed by diluting a breast tumour extract with a high PSA concentration ($20.4 \mu\text{g/L}$) with either a 6% (w/v) bovine serum albumin solution or a PSA-negative breast tumour extract. The obtained values, at dilutions ranging from 2 to 32-fold, were very close to those predicted by the PSA-value in the undiluted specimen ($100 \pm 5\%$). A batch of 16 breast tumour extracts (four with PSA $<0.05 \mu\text{g/L}$ and twelve with PSA $>1 \mu\text{g/L}$) were also sent to two different laboratories performing routine PSA assays by the Hybritech and DPC methods. In both cases, their values were very similar to the ones obtained by our method, in our laboratory. These data further demonstrate that the invention's PSA detection results are not due to any non-specific effects and that contamination is very unlikely.

Although we describe detection of PSA with a time-resolved immunofluorometric technique, it is understood that those skilled in the art may use other presently available or future developed immunological techniques for PSA quantification to at least 0.03 ng/mg of total protein. For example, techniques capable of such sensitivity include chemiluminescence with acridinium esters as labels, enzymatically triggered chemiluminescence with alkaline phosphatase and dioxetanes substrates luminol chemiluminescence enhanced by horseradish peroxidase, immunoassays using alkaline phosphatase and the fluorogenic substrate 4-methylumbelliferyl phosphate or p-nitrophenyl phosphate, immunoassay using horseradish peroxidase and substrates like ABTS® and tetramethylbenzidine and time-resolved immunofluorometric assays with Eu^{3+} as label.

In addition, PSA expression may also be detected by determining whether mRNA for PSA is present in a breast tumour sample. The preferred procedure for detecting mRNA for PSA is by PCR amplification. mRNA is isolated from breast tumour samples and cDNA synthesized by reverse transcription. PCR amplification of cDNA is accomplished using PSA specific primers. A probe is used to detect cDNA for PSA. Other methods for detecting an RNA for PSA may also be used, such as, the Northern Blot technique.

For most of the tumour extract samples analyzed for PSA, data for oestrogen (ER) and progesterone (PR) receptor concentrations was available. Also 474 samples were analyzed for the presence of the p53 tumour suppressor gene product, using a method previously described (14). Tumours were then classified as being positive or negative for ER, PR, p53 and PSA using the following negativity cutoff levels: $<10 \text{ fmol/mg}$ of total protein for ER and PR (14, 30,31); $<3 \text{ U/L}$ for p53 (equivalent to 0.02 ng/mL) (14) and $<0.05 \mu\text{g/L}$ for PSA. The data are summarized in Table II.

There is a significant association between the presence of oestrogen and/or progesterone receptors and the presence of PSA in the tumours ($P<0.002$). PSA is independently associated with ER and PR because tumours which are either ER(+) only or PR(+) only still have higher percentage of positivity for PSA in comparison to tumours which are negative for both receptors.

Additionally, the highest percentage of PSA-positive tumours is associated with tumours that are positive for both the ER and PR (Table II). There is no association between the presence of PSA and the presence of the p53 tumour suppressor gene product ($P=0.37$). It has recently been shown that the latter is strongly associated with oestrogen and/or progesterone receptor-negative tumours (14) an association also shown in Table II for the samples of this study

($P < 0.001$).

Correlation studies using linear regression analysis between ER and PR and PSA, for all samples of this study ($N=525$) gave the following Pearson correlation coefficients: $r = -0.023$, not significantly different from zero (NS), $P = 0.60$ for ER and $r = -0.015$, (NS), $P = 0.71$ for PR. When only the PSA-positive tumours were used for correlation ($N=151$) the following Pearson correlation coefficients were obtained: $r = -0.015$, (NS), $P = 0.85$ for ER and $r = -0.068$, (NS), $P = 0.40$ for PR.

Some breast tumours had very high PSA levels. Highest values were obtained for five tumours in which PSA levels were $>20 \mu\text{g/L}$ in the extracts and between 200-1000 ng of PSA per g of breast tumour tissue.

Association analysis between PSA presence in breast tumours and patient age gave the results shown in Table III and Figure 3. PSA was distributed preferentially in younger (premenopausal) patients and this preference was statistically significant ($P = 0.012$).

Tumour stage was available in 203 patients. The results of the distribution of PSA-positive tumours in various stages is given in Table IV and Figure 4. Clearly, there is a trend for the PSA-positive tumours to be preferentially associated with lower disease stage.

PSA-positive tumours are predominantly ER(+) and PR (+). The presence of PSA in a tumour is indicative of functional ER and PR because PSA is closely associated with the PR (Table V). PR is a product of the action of the ER and is indicative of functional ER. Thus, monitoring PSA would be a useful test to identify patients who possess functional ER and PR. These patients are the ones most likely to respond to endocrine treatment which currently consists of administering one or more of the following: Antioestrogens, antiprogestins, antiandrogens, progestins, androgens, glucocorticoids. Thus, the classification of patients as PSA(+) and PSA(-) may be useful to select those who will benefit from endocrine treatment.

In addition, a subgroup of PSA-positive and ER-negative patients was surprisingly found to have a good prognosis and respond well to endocrine treatment. In order to examine the prognostic significance of PSA in the subsets of patients who are ER-negative or ER-positive, the hazard ratio between PSA-positive and PSA-negative patients was calculated for two subsets being the ER-negative and the ER-positive groups, using the Cox regression model. The analysis was done at two cut-off levels of the receptors, 10 fmol/mg or 20 fmol/mg since with the receptor assays used, levels between 10-20 fmol/mg are considered equivocal. The results of the analysis are shown in Table 6. In the ER-positive group the risks of relapse were almost identical between PSA-positive and PSA-negative patients, which was expected since it is known that steroid hormone receptors are favourable prognostic indicators in breast cancer. However, in the ER-negative group, the risk of relapse was substantially reduced when the tumours were PSA-positive (hazards ratio 0.13-0.20). The difference was statistically significant when the cutoff level of the receptors was 20 fmol/mg due to the increase in the number of patients in this subgroup. The hazards ratio in the ER-negative subgroup remained very low even when nodal status, clinical stage and histological type were controlled in the analysis.

The risk for cancer relapse was significantly lower in patients with PSA-positive tumours than in patients with PSA-negative tumours. The hazard ratio for relapse of PSA-positive patients and PSA-negative patients was 0.32. A similar hazard ratio for overall survival was also observed. Overall and relapse-free survival curves are shown in Figure 6. The probabilities of relapse-free and overall survivals were substantially higher in the PSA-positive patients than in the PSA-negative ones. Figure 6 demonstrates that PSA-positive patients relapse less frequently and live longer than PSA-negative patients and that this difference is statistically significant ($P = 0.06$ and 0.04 , respectively). Of the 174 patients, 42 had cancer relapse and 27 died. The overall follow-up time for these patients ranged between 7 and 67 months with a median of 33 months. PSA immunoreactivity higher than 0.03 ng/mg was detected in 27% of the patients (47/174). Without considering the follow-up time PSA-positive patients were less likely to relapse or die than PSA-negative patients (11% of PSA-positive patients versus 29% of PSA-negative patients for cancer relapse and 6% of PSA-positive patients versus 19% of PSA negative patients for death).

The data shows that breast tumours produce PSA, an antigen that was originally thought to be highly specific for the prostate. Previous immunohistochemical studies found no PSA immunoreactivity in breast or other tumours (17) or found occasional PSA immunoreactivity with polyclonal but not monoclonal antibodies, suggesting cross-reactivity effects (18).

The percentage of tumours producing PSA is significant (approximately 29%) similar or higher to the percentage of tumours with amplification of the HER-2 oncogene (19). The PSA form in the tumour has a molecular weight of approximately 30 KD and corresponds to the free PSA molecule.

The production of PSA by breast tumours is due to PSA gene derepression by steroid hormone receptors bound to either oestrogens, progestins or androgens (Figure 5). This is indicated by the finding that most tumours producing PSA are steroid hormone receptor-positive. From the 151 PSA-positive tumours, only 20 were negative for oestrogen and/or progesterone receptors. From these, fifteen had detectable oestrogen and/or progesterone receptor levels but their concentration was below the cutoff point of 10 fmol/mg of protein. Only five PSA-positive tumours (3.3%) had undetectable oestrogen and progesterone receptor levels by the method used. In these five tumours the PSA immunoreactivity of the extracts was relatively low (0.05, 0.06, 0.14, 0.17 and $0.37 \mu\text{g/L}$).

Recent reports suggest that PSA expression in the prostate may be under the direct influence of hormones, namely synthetic androgens or testosterone (20-23). Our observation that the presence of PSA in breast tumours is dependent upon the presence of the steroid hormone receptors and that there is no correlation between levels of PSA and receptors, indicate that the receptors are necessary but not sufficient for PSA production. In addition, one or more as yet unidentified ligands interact with the steroid hormone receptors to form a complex that regulates PSA gene derepression (Figure 5). Active ligand-receptor complexes apparently exist in only 32% of the steroid hormone receptor-positive tumours. It is not clear if in the rest of the steroid hormone receptor-positive tumours the ligand(s) is/are absent, the receptors are defective as previously suggested (24) or the ligand-receptor complexes are formed but are somehow ineffective at the level of gene derepression.

This mechanism for PSA gene derepression in breast cancer is further supported by the finding that PSA production is associated with younger patient age ($P=0.012$, Table 3). In patients over the age of 55, only 24% of tumours produce PSA even if the oestrogen or progesterone receptor-positive tumours are over 80% of the total. In patients under the age of 35, 33% of tumours produce PSA even if the oestrogen and/or progesterone receptor-positive tumours are only 50% of the total. To further demonstrate the effect of age on PSA production the percentage of tumours that produce PSA from the total number of oestrogen or progesterone receptor-positive tumours was calculated. These values are 67% (6/9) and 75% (6/8), respectively, for the age group <35 years and 29.7% (80/269) and 38.1% (30/210), respectively, for the age group >55 years (data from Table 3). The higher PSA positivity rate among younger patients may be related to production of the putative ligands of Figure 5 by the functioning ovaries.

The higher PSA positivity rates among tumours which are positive for both oestrogen and progesterone receptors and the intermediate positivity rates among tumours which are positive for only oestrogen or only progesterone receptors, in comparison to the tumours which are negative for both receptors (Table II) demonstrate that either receptor can drive the production of PSA as seen in Figure 5.

Although disease stage was available only for 203 patients, the association analysis between PSA production and disease stage demonstrates (Table IV and Figure 4) that there is a clear trend for PSA-positive tumours to be preferentially associated with lower disease stage. The P values did not fall below 0.05 because of the relatively small number of samples in some patient groups.

A practical implication of these findings is that the PSA gene repression mechanism may be used for treatment of breast tumours. An examination of the ligands involved in steroid hormone receptor binding and PSA gene regulation in breast cancer may assist in this treatment. Breast tumours producing PSA constitute a sizable group (29% of patients) which may be examined in retrospective or prospective studies to establish if patients have a different prognosis or favourable response to selected therapy.

The data indicates that PSA is a favourable prognostic indicator because it is associated more strongly with tumours that are positive for both receptors, with lower disease stage and with improved patient survival (Figure 6). In the breast tumour, PSA is present in the free 30 kD, presumably enzymatically active form. The suggested mode of PSA production (Figure 5) based on the findings that the overwhelming majority of PSA-positive tumours have detectable receptors (146/151 or 97%) and that younger patients are more positive than older patients, lead to the conclusion that the PSA-positive tumour is a subgroup that possesses "effective" receptors, capable of gene regulation, as exemplified by PSA production. Then PSA-positive tumour patients will be most likely to respond to steroid hormone therapy. This was recently suggested for the steroid hormone receptor-inducible pS₂-BCE1 protein, another potential prognostic indicator in breast cancer (25, 26).

A significant proportion of breast tumours (29%) produce PSA. PSA production is associated with steroid hormone receptor-positive tumours, younger age and earlier disease stage. PSA can be used as a routine prognostic marker for breast carcinoma and may play a role in disease initiation and progression. The invention's time-resolved fluoroimmunoassay is sensitive enough to detect levels of PSA as low as 0.05ug/L in breast tumour extracts which equivalent to approximately 0.03 ng of PSA per mg of total protein.

In order that the invention may be more fully understood, the following Example is given by way of illustration only.

EXAMPLE

METHODS

Patients - Breast Tumours

Approximately 500 breast tumour extracts were analysed for steroid hormone receptors, for the p53 tumour suppressor gene product and for PSA, using the invention's new, highly sensitive immunofluorometric procedure.

All primary tumours used in this study were collected from about ten different hospitals in Ontario. Primary breast tumour tissue was immediately stored in liquid nitrogen after surgical resection, transported to the laboratory and stored subsequently at -70°C until extraction was performed (~1-2 weeks). Approximately 0.5g of tumour tissue was weighed

out, smashed with a hammer if necessary, and pulverized in a Thermovac tissue pulverizer with liquid N₂. The resulting powder was transferred into 50mL plastic tubes along with 10 mL of extraction buffer (0.01 mol/L Tris, 1.5 mmol/L ethylenediaminetetraacetic acid, 5 mmol/L sodium molybdate, pH adjusted to 7.40 with 5 mol/L HCl). The tissue powder was homogenized on ice with a single 5s burst of a Polytron homogenizer. The particulate material was pelleted by centrifugation at 105,000 g. The intermediate layer (cytosol extract) was collected without disturbing the lipid or particulate layers. Protein concentration of the cytosol extract was determined by the Lowry method and the extracts were stored at -70°C until analysis (up to three weeks). In determining the total protein of tumour tissue sample to be tested, the protein concentration of the extract may provide the basis for such determination. Hence, the detection level of 0.03 ng of PSA per mg of total protein is determinative for deciding PSA (+ve) or (-ve). Stability studies have revealed that the p53 protein and PSA in cytosol extracts are stable for a least four months at -70°C.

Oestrogen and Progesterone Receptors

Quantitative analysis of oestrogen and progesterone receptors (ER, PR) was measured using the Abbott enzyme immunoassay kits (Abbott Laboratories, North Chicago, IL 60064). The kits were used according to the manufacturer's instructions.

PSA and p53 Measurement

Analysis of PSA and p53 was performed using the invention's time-resolved fluoroimmunoassay.

Instrumentation

For measuring liquid-phase Tb³⁺ fluorescence in white microtiter wells, we used the CyberFluor 615® Immuno-analyzer, a time-resolved fluorometer. The time-gate settings of the instrument and the interference filter in the emission pathway were the same as described elsewhere (32,33).

PSA MEASUREMENT

Reagents and Solutions

All reagents were purchased from Sigma unless otherwise stated. The coating solution was a 50 mmol/L Tris buffer, pH 7.80, containing 0.5 g of sodium azide per litre. The wash solution was a 5 mmol/L Tris buffer, pH 7.80, containing 0.15 mol of NaCl and 0.5 g of polyoxyethylenesorbitan monolaurate (Tween 20) per litre.

The substrate buffer was a 0.1 mol/L Tris buffer, pH 9.1, containing 0.15 mol of NaCl, mmol MgCl₂ and 0.5 G of sodium azide per litre. The substrate stock solution is a 10 mmol/L diflunisal phosphate (DFP) solution in 0.1 mol/L NaOH. It is available from CyberFluor Inc., Toronto, Canada. The developing solution contains 1 mol Tris base, 0.4 mol NaOH, 2 mmol, TbCl₃ and 3 mmol of EDTA per litre (no pH adjustment). This solution is prepared as described previously (23, 24) and is commercially available by CyberFluor. The assay buffer is a 50 mmol/L Tris buffer, pH 7.80, containing 60 g of BSA, 0.5 mol of KCl, 0.5 g of sodium azide, 50 mL of normal mouse serum and 5 g of Triton X-100 per litre. The polyclonal biotinylated detection antibody and SA-ALP diluent is a 50 mmol/L Tris buffer, pH 7.80, containing 60 g of BSA per litre. The GARlg-ALP conjugate diluent is the same as the polyclonal biotinylated detection antibody diluent but also contains 4% (v/v) of goat serum. The blocking solution was a 50 mmol/L Tris buffer, pH 7.80, containing 10 g of BSA per litre.

Antibodies

The mouse monoclonal MBP0405 and the rabbit polyclonal PBG0101 anti-PSA antibodies were purchased from Medix Biotech, Foster City, CA 94404. The SA-ALP conjugate was purchased from Jackson ImmunoResearch, West Grove PA 19390. The alkaline phosphatase-conjugated affinity purified goat anti-rabbit IgG, Fc fragment specific (GARlg-ALP) was also purchased from Jackson. A polyclonal rabbit antibody against α_1 -antichymotrypsin was purchased from Dakopatts (Glostrup, Denmark).

Standards

Because of the unavailability of a universally accepted standard from PSA, for our studies we used PSA standards in a 50 mmol/L Tris buffer, pH 7.80, containing 6% (w/v) of BSA. A stock PSA solution, prepared from PSA purified from human seminal plasma, was purchased from Scripps Laboratories, San Diego, CA 92121. Our final standard

solutions were calibrated against standards from the Hybritech Tandem-PSA kit (Hybritech Inc., San Diego, CA 92126). For routine use we recommend six PSA standards with concentrations of 0, 0.025, 0.1, 0.5, 2 and 10 µg/L. These are stable for at least one month at 4°C.

5 Biotinylation of the Polyclonal Anti-PSA Antibody

The polyclonal anti-PSA antibody, purified by ionexchange chromatography, was dialyzed overnight against five litres of a 0.1 mol/L sodium bicarbonate solution. This stock solution (-2 mg/ml) was diluted 2-fold with a 0.5 mol/L carbonate buffer, pH 9.1. To this solution we added 1 mg of NHS-LC-Biotin (from Pierce Chemical Co., Rockford, IL) dissolved in 50 µL of dimethylsulfoxide, under continuous stirring and incubated for 2 h at room temperature. This biotinylated antibody was used without further purification and stored at 4°C for at least six months.

Coating of Microtiter Wells

15 White, opaque 12-well microtiter polystyrene strips were obtained from Dynatech Laboratories, Alexandria, VA 22314. The wells were coated overnight at room temperature with 500 ng/100 µL/well of coating monoclonal anti-PSA antibody in the coating buffer. Before use, the wells were washed x 2 and blocked for 1 hour with 200 µL/well of the blocking solution.

20 Assay Procedure

Wash the strips x 6. In each well pipet 50 µL of tumour tissue extract or PSA standards and add 50 µL of assay buffer per well. Incubate for 3 h at room temperature with continuous mechanical shaking and wash x 6. Add 100 µL per well of the biotinylated polyclonal rabbit detection antibody diluted 1,000-fold in the polyclonal detection antibody diluent (100 ng of antibody per well). Incubate for 1 h as above and wash x 6. Add 100 µL per well of SA-ALP conjugate diluted 30,000-fold in the SA-ALP diluent (3 ng of conjugate per well). Incubate for 15 min as above and wash x 6. Add 200 µL/well of the DFP substrate diluted 10-fold just before use in the substrate buffer (working DFP substrate solution is 1 mmol/L) and incubate for 10 min at room temperature with shaking. Add 100 µL/well of the developing solution, mix by shaking for 1 min and read the Tb³⁺-specific fluorescence with the CyberFluor 614 Immunoanalyzer. Data reduction is automatic.

Assay of the PSA- α_1 -Antichymotrypsin Complex (PSA-ACT)

35 This assay is exactly the same as the PSA assay described above but instead of using the biotinylated polyclonal rabbit anti-PSA antibody, we used the polyclonal rabbit α_1 -antichymotrypsin antibody, diluted 500-fold in the SA-ALP conjugate diluent. We then added 100 µL of a 5,000-fold diluted FARlg-ALP conjugate (20 ng per well) and incubated for 30 min with shaking. After washing x 6, we completed the assay by adding the DFP substrate as described in the PSA assay. No effort was made to calibrate this assay because of the unavailability of standard PSA-ACT complex.

PSA was also measured in selected tumour extracts with commercially available kits (a). The Hybritech Tandem® R PSA kit (Hybritech Inc, San Diego, CA 92126), (b). The IRMA-Count® PSA kit (Diagnostic Products Corp., Los Angeles, CA 90045) and (c). The Abbott IMx® automated PSA method (Abbott Laboratories, Chicago, IL., U.S.A.). High performance liquid chromatography was performed with a Shimadzu system with an absorbance monitor at 280 nm (Shimadzu Corp., Kyoto, Japan), isocratically, using a mobile phase of 0.1 mol/L NaH₂SO₄-0.1 mol/L NaH₂PO₄, pH 6.80. Flow rate was 0.5 mL/min. The gel filtration column used was a Bio-Sil SEC-400, 600 mm x 7.5 mm (BioRad Labs, Richmond, CA). The column was calibrated with a molecular weight standard solution from BioRad, containing thyroglobulin (670 KD), IgG (158 KD) ovalbumin (44 KD), myoglobin (17 KD) and cyanocobalamin (1.4 KD). Fractions of 0.5 mL each were collected with a fraction collector, Model FRAC-100 (Pharmacia, Uppsala, Sweden) after injecting a 150 mL sample.

50 Statistical Analysis

The chi-square (χ^2) test was used to determine the statistical significance of differences in distributions and all chi-square values and the corresponding P values were calculated by the statistical software SAS (SAS Institute Inc., Cary, NC, USA).

p53 Measur m nt**Solutions and Reag nts**

5 Lysis buffer: 150 mM CaCl₂, 20 mM Tris, 1% Nonidet® P-40, 0.5 mM phenylmethanesulfonylchloride (PMSF), 1 µg ml⁻¹ leupeptin, 50 g ml⁻¹ aprotinin. Sample diluent (diluent for cell lysates, serum, polyclonal anti-p53 rabbit antiserum and alkaline phosphatase-conjugated goat anti-rabbit antibody): 50 mM Tris, pH 7.40, containing 60 g bovine serum albumin (BSA) and 1 g sodium azide per litre. Monoclonal anti-p53 antibody diluent; 50 mM Tris, pH 7.40, containing 60 g bovine serum albumin, 1 g sodium azide and 0.5 mol KCl per litre.

10 Substrate buffer 0.1 M Tris, pH 9.1, 0.15 M NaCl, 1 mM MgCl₂. Developing solution: 2 x 10³ TbCl₃, 3 x 10⁻³ EDTA, 0.4 M NaOH, 1M Tris base (no Ph adjustments). Prepare as described elsewhere (32). Wash solution: Distilled water. Coating buffer: 50 mM Tris, pH 7.80, containing 1 g of sodium azide per litre. The phosphate ester of 5-fluorosalicylic acid (FSAP) was obtained from CyberFluor Inc., Toronto, Canada. It is stored as a 10 mM stock solution in 0.1 M NaOH at 4°C for many months. This stock is diluted 10-fold in the substrate buffer just before use. All other chemicals were
15 from Sigma Chemical Co., St. Louis MO, USA, except Nonidet® P-40 (Boehringer-Mannheim, Indianapolis, IN, USA) TbCl₃·6H₂O IGFS Chemicals, Columbus, OH, USA) and the biotinylation reagent NHS-LC-Biotin (Pierce Chemical Co., Rockford, IL, USA).

p53 Standards

20 Recombinant mutant human p53 protein standards in the range from 0.25-4 ng ml⁻¹ were obtained from Oncogene Science, Inc., Uniondale, NY, USA and were considered the primary standards. These standards were used to optimize the assay and standardize cell lysates for subsequent studies. Another human wild-type recombinant p53 solution, prepared as described elsewhere (33) was a gift to us by Dr. C. Prives, Columbia University. This p53 preparation was
25 diluted in the sample diluent to make standard solutions.

Antibodies

30 The mouse anti-p53 monoclonal antibodies, PAb 421 and PAB 240 were kindly provided by Dr. S. Behchimol, Ontario Cancer Institute. These are tissue culture supernatants containing approximately 30 µg ml⁻¹ antibody. The rabbit polyclonal anti-p53 antibody, CM-1, was obtained from Dimension Labs, Mississauga, Ontario, Canada. The goat anti-rabbit antibody, conjugated to alkaline phosphatase and the goat anti-mouse antibody, F_c specific, both approximately 1 mg ml⁻¹, were obtained from Jackson ImmunoResearch, West Grove, PA, USA.

Immunoassay of p53

35 White, opaque, 12-well microtiter strips (Dynatech Labs, Alexandria, CA< USA) were coated with a goat anti-mouse antibody by pipetting 100 µl containing 500 ng well⁻¹ of the antibody solution in the coating buffer. After overnight incubation at room temperature, the wells were washed four times with distilled water. The wells were then blocked by
40 pipetting 200 µl well of the sample diluent, incubating for 1 h and washing as above. The wells were then used for the assay as follows. We add 100 ng well⁻¹ of mouse monoclonal anti-pt3 antibody (PAB 421 or PAB 240) and 50 µl of sample (p53 standards of cell lysates). The antibodies are cell culture supernatants containing about 30 µg ml⁻¹ of antibody and they were diluted x 20 in the monoclonal anti-p53 antibody diluent. The cell lysates were used in different dilutions in the sample diluent, varying from 10-1000-fold. After 3 h incubation with shaking at 37°C, the plates were
45 washed x 4. We then added 100 µl well⁻¹ of the polyclonal rabbit anti-p53 antibody (diluted 5000-fold in the sample diluent) and incubated with shaking for 1 h at room temperature. After washing x 4, we added 100 µl well⁻¹ of the goat anti-rabbit alkaline phosphatase conjugate solution (diluted 5000-fold in the sample diluent) and incubated with shaking for 1 h at room temperature. The strips were washed again x 4 and 100 µl well⁻¹ of the FSAP solution (10⁻³ M in the substrate buffer) were added and incubated for 10 min with shaking at room temperature. The fluorescent complex
50 was then formed by adding 100 µl well⁻¹ of the developing solution followed by brief mixing for 1 min. Time-resolved fluorometric measurements at 615 nm were performed on the CyberFluor 615 Immunoanalyzer. Data reduction and plotting of calibration curves was automatic through the analyzer software.

Detection of PSA mRNA

55 Detection of PSA mRNA can be accomplished by the method of Deguchi et al or a modification of it. This method involves isolation of mRNA from tumours, synthesis of cDNA by reverse transcription and PCR amplification of the cDNA using PSA specific primers. The sequence of primers used are as follows:

5' - TCG-GCA-AGT-TCA-CCC-TCA-3'
 5' - CCC-TCT-CCT-TAC-TTC-ATC-C-3'.

PCR amplification produces a fragment of 754 base pairs which is electrophoresed on agarose gels and Southern blotted to Hybond N+ membrane. A probe (5' - GGA-ACC-TTG-GAA-ATG-ACC-AG-3') labeled with fluorescein is added to hybridize with cDNA for PSA. The probe is detected using chemiluminescence reagents from Amersham International.

Breast Cancer Survival and ER-negative, PSA-positive Study

One hundred and seventy four patients with primary breast cancer were included in this study. All patients were treated and followed at the Department of Gynecologic Oncology at the University of Turin. Ages of these patients ranged from 25 to 91 years with a median of 56 years. Thirty two percent of the patients were <50 years and 69% >50 years. The follow-up time ranged from 7 to 67 months with a median of 33 months.

Clinical and pathological information, including clinical stage, histological cell type and grade, axillary node involvement, tumour size, presence of ER and PR in tumour cells and adjuvant treatment after surgery, was collected for each patient. According to the TNM staging system, 45%, 47% and 8% of the patients had stage I, II and III or IV, respectively. Each breast cancer specimen was also histologically graded and typed. Thirty nine percent of patients had low grade (I), 42% had moderate grade (II), and 19% had high grade (III). Seventy percent of patients had ductal carcinomas. The rest had lobular (13%), lobular in situ (2%), medullary (5%), papillary (2%), tubular (2%), tubulo-lobular (3%), or unknown types (3%). In the data analysis, histological type was grouped into two categories, i.e. ductal versus non-ductal, because of the small number of patients who had types other than ductal carcinomas.

The size of tumour in these patients ranged from 0.7 to 6 cm, and median and mean sizes were identical, 2.4 cm. Fiftyone percent of the patients had tumour invading the axillary lymph nodes. Of the 174 patients, 56% were treated with adjuvant therapy as follows: tamoxifen (37%), chemotherapy (15%), or both (4%). The rest (44%) received no further treatment after surgery.

Demographic, clinical and pathological variables, including age, clinical stage, histological grade and type, nodal status, tumour size, ER and PR, and adjuvant treatment, were compared between PSA-positive and PSA-negative groups, using the contingency table and Chi-square test in order to examine the associations between PSA and these variables. The relationship between each of the study variables and relapse-free or overall survival was expressed by the hazard ratio and its 95% confidence interval, which was calculated univariately using the Cox proportional hazard regression model (35). The multivariate Cox regression model was also employed to evaluate the impact of PSA immunoreactivity on patient survival while controlling for other clinical and pathological variables which may also affect the survival, such as clinical stage (I, II or III/IV), nodal status (positive or negative), tumour size (greater or less than mean size), steroid hormone receptors (presence or absence), and adjuvant treatment (none, tamoxifen, or both tamoxifen and chemotherapy).

Kaplan-Meier relapse-free and overall survival curves (36) were constructed to demonstrate the survival difference between PSA-positive and negative groups. The logrank test (37) was used to examine the significance of the differences between survival curves.

Table I.

Analysis of PSA in Breast Tumour Extracts				
	PSA, mg/L			
Number of Patients	<0.05	≥0.05	≥0.10	≥0.30
525	374	151	96	49
% of Samples	71.2%	28.8%	18.3%	9.3%

Table II

Relationship Between Oestrogen and Progesterone Receptors, PSA and p53 Levels in Breast Tumour Extracts ¹			
Samples (N=525)	PSA (+) (%)	PSA (-) (%)	P Value
ER(+) 393 ER (-) 132	127 (32.3) 24 (18.2)	266 (67.7) 108 (81.8)	0.002
PR(+) 321 PR (-) 204	111 (34.6) 40 (19.6)	210 (65.4) 164 (80.4)	<0.001
ER (+) or PR (+) 407 ER (-) and PR (-) 118	131 (32.2) 20 (16.9)	276 (67.8) 98 (83.1)	0.001
ER(+) and PR(+) 307 ER(+) and PR(-) 86 ER(-) and PR(+) 14 ER(-) and PR(-) 118	107 (34.8) 20 (23.3) 4 (28.6) 20 (16.9)	200 (65.2) 66 (76.7) 10 (71.4) 98 (83.1)	0.002
Samples (N=558)	p53 (+) (%)	p53 (-) (%)	P Value
ER(+) 416 ER (-) 142	64 (15.4) 50 (35.2)	352 (84.6) 92 (64.8)	<0.001
PR(+) 338 PR (-) 220	47 (13.9) 67 (30.4)	291 (86.1) 153 (69.6)	<0.001
ER (+) or PR(+) 428 ER (-) and PR (-) 130	68 (15.9) 46 (35.4)	360 (84.1) 84 (64.6)	<0.001
Samples (N=474)	p53 (+) (%)	p53 (-) (%)	P Value
PSA(+) 90 PSA (-) 384	20 (22.2) 103 (26.8)	70 (77.8) 281 (73.2)	P=0.37

1. For negativity cutoff levels see text. Values in brackets are percentages.

Table III

Distribution of PSA-Positive, Oestrogen Receptor-Positive and Progesterone Receptor-Positive Tumours in Various Age Groups			
	% of Positive Tumours ¹		
Patient Age (Years)	PSA (+)	ER (+)	PR (+)
< 35 (N=18)	33.3 (6/18)	50.0 (9/18)	44.4 (8/18)
35-44 (N=66)	36.4 (24/66)	71.2 (47/66)	62.1 (41/66)
45-54 (N=104)	38.5 (40/104)	64.4 (67/104)	58.7 (61/104)
>55 (N=336)	23.8 (80/336)	80.1 (269/336)	62.5 (210/336)
P Value(2)	0.012	0.001	0.45

1. In brackets are numbers of positive tumours per total number of tumours in each group. N=number of patients per group.

2. P value for comparing the distribution of positive or negative tumours for each parameter, in the various age groups.

Table IV

Association of PSA-Positive Tumours with Disease Stage	
Disease Stage	% of PSA-Positive Tumours ¹
0	42.9 (6/14)
1	30.7 (35/114)
2	22.0 (13/59)
3	12.5 (2/16)
P	0.18
0-1	32.0 (41/128)
2-3	20.0 (15/75)
P	0.06

(1) In brackets are numbers of positive tumours per total number of tumours in each group.

Table V

Relationship between PSA Immunoreactivity and ER & PR

Receptor Status	No. of Patients	No. of PSA +	OR & 95 % CI	p value
ER-, PR-	226	32 (14%)	1.00	
ER+, PR-	139	28 (20%)	1.53 (0.88-2.67)	0.13
ER-, PR+	58	24 (41%)	4.28 (2.25-8.14)	<0.01
ER+, PR+	852	302 (35%)	3.33 (2.23-4.96)	<0.01

OR: Odds ratio.

CI: Confidence interval.

Table VI

Associations between PSA and relapse-free survival stratified by the status of oestrogen receptors				
ER status	PSA(+)		Hazards Interval	95% confidence P value
	patients	ratio ¹		
ER cutoff at 10 fmol/mg				
Univariate analysis				
ER(+) (n= 112) ²	36	0.98	0.37-2.61	0.97
ER(-) (n= 57)	9	0.16	0.02-1.22	0.08
Multivariate analysis ³				
ER(+) (n=112)	36	0.80	0.27-2.32	0.68
ER(-) (n= 57)	9	0.13	0.02-1.15	0.07
ER cutoff at 20 fmol/mg				
Univariate analysis				
ER(+) (n= 95)	27	1.42	0.46-4.34	0.54
ER(-) (n= 74)	18	0.18	0.04-0.76	0.02
Multivariate analysis ³				
ER(+) (n= 95)	27	0.96	0.27-3.33	0.94
ER(-) (n= 74)	18	0.20	0.04-0.93	0.04

1. The ratio of hazards between PSA-positive and PSA-negative patients.

2. N=number of patients.

3. Adjusted for age, clinical stage, nodal status, tumour size, and histological grade.

REFERENCES

- Harris, J.R., Lippman, M.E., Veronesi, U., Willett, W. Breast cancer, (first of three parts). *New Engl. J. Med.*, 1992; **327**: 319-28.
- Harris, J.R., Lippman, M.E., Veronesi, U., Willett, W. Breast cancer, (second of three parts). *New Engl. J. Med.*, 1992; **327**: 390-8.
- Harris, J.R., Lippman, M.E., Veronesi, U., Willett, W. Breast cancer, (third of three parts). *New Engl. J. Med.*, 1992; **327**: 473-80.
- McGuire, W.L., Clark, G.M. Prognostic factors and treatment decisions in axillary node-negative breast cancer. *New Engl. J. Med.*, 1992; **326**: 1756-61.
- McGuire, W.L., Tandon, A.K., Craig Alfred, D., Chamness, G.C., Clark, G.M. How to use prognostic factors in axillary node-negative breast cancer patients. *J. Natl. Cancer Inst.*, 1990; **82**: 1006-15.
- Muss, H.B. Endocrine therapy for advanced breast cancer: a review. *Breast Cancer Res. Treat.*, 1992; **21**: 15-26.
- Carter, H.B., Coffey, D.S. The prostate: an increasing medical problem. *The Prostate*, 1990; **16**: 39-48.
- Nomura, A.M.Y., Kolonel, L.N. Prostate cancer: A current perspective. *Am. J. Epidemiol.*, 1991; **133**: 200-27.
- Bruchovsky, N., Brown, E.M., Coppin, C.M., et al. The endocrinology and treatment of prostate tumour progression. *Prog. Clin. Biol. Res.*, 1987; **239**: 347-57.
- Thompson, T.C. Growth factors and oncogenes in prostate cancer. *Cancer Cells*, 1990; **2**: 345-354.
- Oesterling, J.E. Prostate specific antigen: a critical assessment of the most useful tumour marker for adenocarcinoma of the prostate. *J. Urol.*, 1991; **145**: 907-923.
- Diamandis, E.P. Immunoassays with time-resolved fluorescence spectroscopy. Principles and applications. *Clin. Biochem.*, 1988; **21**: 139-150.
- He, Y., Diamandis, E.P. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum. *Clin. Chem.*, 1993 (in press).
- Hassapoglidou, S., Diamandis, E.P., Sutherland, D.J.A. Quantification of p53 protein in tumour cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. *Oncogene*, 1993 (in press).
- Stenman, U.H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., Alfthan, O. A complex between prostate-specific antigen and α_1 -antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. *Cancer Res.*, 1991; **51**: 222-6.

16. Lilja, H., Christensson, A., Dahlen, U., et al. Prostate-specific antigen in serum occurs predominantly in complex with α_1 -antichymotrypsin. *Clin. Chem.*, 1991; **37**: 1618-25.
17. Ford, T.F., Butcher, D.N., Masters, J.R.W., Parkinson, C.M. Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice. *British J. Urol.*, 1985; **57**: 50-5.
18. Papotti, M., Paties, C., Peveri, V., Moscuza, L., Bussolati, G. Immunocytochemical detection of prostate-specific antigen (PSA) in skin adnexal and breast tissues and tumours. *Bas. Appl. Histochem.*, 1989; **33**: 25-9.
19. Slamon, D.J., Clark, G.M., Wong, S.G. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science*, 1987; **235**: 177-82.
20. Wolf, D.A., Schulz, P., Fittler, F. Transcriptional regulation of prostate kallikrein-like gene by androgen. *Mol. Endocrinol.*, 1992; **6**: 753-62.
21. Henttu, P., Liao, S.S., Vihko, P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA) but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line. *Endocrinology*, 1992; **130**: 766-72.
22. Montgomery, B.T., Young, C.Y., Bilhartz, D.L., Andrews, P.E., Prescott, J.L., Thompson, N.F. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostate adenocarcinoma cell line, LNCaP. *Prostate*, 1992; **21**: 63-73.
23. Weber, J.P., Oesterling, J.E., Peters, C.A., Partin, A.W., Chan, D.W., Walsh, P.C. The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostate hyperplasia. *J. Urol.*, 1989; **141**: 987-91.
24. Wei, L.L. Transcriptional activation of the oestrogen receptor. *Clin. Chem.*, 1993; **39**: 341-45.
25. Milgrom, E. The oestrogen-regulated pS₂-BCE1 protein in breast cancer. In: Goldhirsch, A., ed. *Endocrine therapy of breast cancer V*. Berlin: Springer Verlag, 1992: 17-22.
26. Foekens, J.A., Rio, M.C., Seguin, P., et al. Prediction of relapse and survival in breast cancer patients by pS₂ protein status. *Cancer Res.*, 1990; **50**: 3832-7.
27. Rochefort, H. Cathepsin D in breast cancer. *Breast Cancer Res. Treat.*, 1990; **16**: 1-13.
28. Silvestrini, R., Veneroni, S., Benini, E., DiFronzo, G., Daidone, M.G. p53 and cathepsin D are independent of established prognostic factors in breast cancer. *Int. J. Oncol.* 1992; **1**: 507-12.
29. Allred, D.C., et al. Association of p53 Protein Expression with Tumour Cell Proliferation Rate and Clinical Outcome in Node-Negative Breast Cancer. *J. Natl. Cancer Inst.* 1993; **85**: 200-206.
30. Thor, A.D., et al. Accumulation of p53 Tumour Suppressor Gene Protein: An Independent Marker of Prognosis in Breast Cancers. *J. Natl Cancer Inst.* 1992; **84**: 845-855.
31. Henderson, I.C. (1991). In *Breast Diseases*, Harris, J.R., Hellman, S., Henderson, I.C., Kinne, D. (eds). J.P. Lippincott: Philadelphia. pp. 332-346.
32. Christopoulos, T.K. and Diamandis, E.P. (1992) *Anal. Chem.* **64**: 342-346.
33. Wang, E.H., Friedman, P.N., and Prices, C. (1989) *Cell* **57**: 379-392.
34. Deguchi, T. et al. (1993) *Cancer Research* **53**: 5350-5354.
35. Cox, D.R. *J. R. Stat Soc(B)* 1972; **34**: 187-202.
36. Kaplan, E.L. Meier, P. *J. Am. Stat. Assoc.* 1958; **53**: 457-481.
37. Mantel, N. *Cancer Chemother Rep* 1966; **50**: 163-170.

Claims

1. A method for detecting the presence of PSA as a prognostic or predictive indicator of breast carcinoma in female breast tumour tissue, said method comprising conducting a biological assay for the presence of PSA on a sample of breast tumour tissue, said assay being capable of detecting a concentration of at least as low as 0.03 ng of PSA per mg of total protein in the sample.
2. A method according to Claim 1, wherein the assay detects the presence of mRNA for PSA in the sample.
3. A method according to Claim 1 or 2, wherein the assay is conducted on a sample which has been cryogenically frozen.
4. A method according to Claim 1, 2 or 3, wherein upon detection of PSA, said female is classified as PSA positive and indicates hormonal treatment is appropriate for said tumour tissue.
5. A method according to Claim 1, 2, 3 or 4, wherein the assay comprises a time-resolved fluoroimmunoassay including enzyme amplification to detect PSA.

6. A method according to Claim 5, wherein the fluoroimmunoassay comprises the use of a monoclonal/polyclonal antibody combination, said monoclonal antibody being specific to PSA or a PSA complex in tumour tissue and said polyclonal antibody being specific to an immune complex formed between the monoclonal antibody and the PSA or PSA complex, said fluoroimmunoassay enzymatically amplifying a signal indicating the presence of said polyclonal antibody.
7. A method according to Claim 6, wherein serum may be used as a positive control in said assay, and wherein PSA in serum forms a PSA-anti-chymotrypsin complex.
8. A method according to any preceding claim, wherein said PSA is present in breast tumour tissue as free PSA.

Patentansprüche


1. Verfahren zum Ermitteln der Anwesenheit von PSA als prognostischer oder prädiktiver Indikator von Brustkrebs in weiblichem Brusttumorgewebe, wobei das genannte Verfahren die Durchführung einer biologischen Analyse in bezug auf die Anwesenheit von PSA in einer Brusttumorgewebeprobe umfaßt, wobei mit der genannten Analyse geringe Konzentrationen von wenigstens 0,03 ng PSA pro mg des Gesamtproteins in der Probe festgestellt werden können.
2. Verfahren nach Anspruch 1, bei dem die Analyse die Anwesenheit von mRNA für PSA in der Probe ermittelt.
3. Verfahren nach Anspruch 1 oder 2, bei dem die Analyse an einer Probe durchgeführt wird, die kryogenisch eingefroren wurde.
4. Verfahren nach Anspruch 1, 2 oder 3, bei dem die genannte weibliche Person nach dem Ermitteln von PSA als PSA-positiv eingestuft wird, und das anzeigt, daß eine Hormonbehandlung des genannten Tumorgewebes angemessen ist.
5. Verfahren nach Anspruch 1, 2, 3 oder 4, bei dem die Analyse eine zeitaufgelöste Fluoroimmunoanalyse einschließlich enzymatischer Verstärkung zum Ermitteln von PSA umfaßt.
6. Verfahren nach Anspruch 5, bei dem die Fluoroimmunoanalyse die Verwendung einer monoklonalen/ polyklonalen Antikörperkombination umfaßt, wobei der genannte monoklonale Antikörper für PSA oder einen PSA-Komplex im Tumorgewebe spezifisch ist und der genannte polyklonale Antikörper für einen zwischen dem monoklonalen Antikörper und dem PSA oder PSA-Komplex gebildeten Immunkomplex spezifisch ist, wobei die genannte Fluoroimmunoanalyse enzymatisch ein Signal verstärkt, das auf die Anwesenheit des genannten polyklonalen Antikörpers hinweist.
7. Verfahren nach Anspruch 6, bei dem Serum als positive Kontrolle in der genannten Analyse verwendet werden kann und bei dem PSA in Serum einen PSA-Anti-Chymotrypsin-Komplex bildet.
8. Verfahren nach einem der vorherigen Ansprüche, bei dem das genannte PSA in Brusttumorgewebe als freies PSA vorhanden ist.

Revendications

1. Méthode pour détecter la présence de PSA ou de mRNA pour le PSA, en tant qu'indicateur pronostique ou prédictif du cancer du sein dans le tissu des tumeurs du sein chez les femmes, ladite méthode comprenant la réalisation d'un dosage biologique pour déterminer la présence de PSA sur un prélèvement de tissu d'une tumeur du sein, ledit dosage étant capable de détecter une concentration au moins aussi basse que 0,03 ng de PSA par mg de protéine totale dans le prélèvement.
2. Méthode selon la Revendication 1, dans laquelle le dosage détecte la présence d'un mRNA pour le PSA dans le prélèvement.
3. Méthode selon la Revendication 1 ou 2, dans laquelle le dosage est réalisé sur un prélèvement qui a été gelé par

cryogénie.

4. Méthode selon la Revendication 1, 2 ou 3, dans laquelle à la détection du PSA, ladite femme est classée PSA positive et indique qu'un traitement hormonal est approprié pour le tissu de ladite tumeur.
5. Méthode selon la Revendication 1,2,3,ou 4, dans laquelle le dosage comprend un dosage fluoroimmunologique résolu dans le temps avec amplification enzymatique pour détecter le PSA.
6. Méthode selon la Revendication 5, dans laquelle le dosage fluoroimmunologique comprend l'emploi d'une combinaison d'anticorps monoclonaux/polyclonaux, ledit anticorps monoclonal étant spécifique du PSA ou d'un complexe PSA dans le tissu de la tumeur et ledit anticorps polyclonal étant spécifique d'un complexe immun formé entre l'anticorps monoclonal et le PSA ou le complexe PSA, ledit dosage immunologique amplifiant à l'aide d'enzymes un signal indiquant la présence du dit anticorps polyclonal.
7. Méthode selon la Revendication 6, dans laquelle le sérum peut être employé en tant que contrôle positif dans ledit dosage, et dans laquelle le PSA dans le sérum forme un complexe PSA-anti-chymotrypsine.
8. Méthode selon n'importe laquelle des revendications qui précèdent, dans laquelle ledit PSA est présent dans le tissu d'une tumeur du sein en tant que PSA libre.






FIG. 2A.




FIG. 2B.




FIG.3.




FIG.4.




FIG. 5.




FIG.6A.




FIG.6B.